A New, Compelling Reason to Target Hsp90 in Tumor Cells
This article was originally published in Start Up
Executive Summary
The finding that hsp90, a "molecular chaperone" that shuttles proteins throughout cells and performs a critical role in the mitochondria of tumor cells could have a profound influence on the development of an emerging class of drugs. It may help explain the limited effectiveness of current hsp90 inhibitors, which do not get into the mitochondria. The authors of the paper describing the work show that an hsp90 inhibitor that does get into the mitochondria has profound cell-killing capabilities.
You may also be interested in...
Structure Work Unveils a New Apoptosis Drug Target
In 1997, Abbott Lab's Steve Fesik showed how a complex between a survival protein and a cell death-inducing helix interacted, triggering a spate of apoptosis-oriented (programmed cell death) cancer research. Now a research team has identified a distinct and completely unforeseen site on a death protein that activates its cell-killing function, potentially kicking off a renaissance in this still challenging field.
Pfizer's Serenex Acquisition Adds Fuel to Heat Shock Fire
Pfizer's acquisition of Hsp90 specialist Serenex is the biggest direct validation by Big Pharma in this up and coming oncology space. Hsp90, sometimes termed a master regulator, has quickly emerged as an important cancer target and Pfizer's endorsement can only give the field a boost.
Pfizer's Serenex Acquisition Adds Fuel to Heat Shock Fire
Pfizer's acquisition of Hsp90 specialist Serenex is the biggest direct validation by Big Pharma in this up and coming oncology space. Hsp90, sometimes termed a master regulator, has quickly emerged as an important cancer target and Pfizer's endorsement can only give the field a boost.